Among Parkinson’s disease patients with both OFF and dyskinesia, ADS-5102 (amantadine) extended-release reduces disruptive motor episodes and improves function: Analysis of phase 3 trials
Objective: Evaluate the effects of ADS-5102 (amantadine) extended release capsules on motor complications and functional outcomes among patients experiencing both troublesome dyskinesia and OFF (disruptive…Clinical Implication of Stimulus Induced Dyskinesia in Pallidal Deep Brain Stimulation for Advanced Parkinson’s Disease
Objective: To investigate the influence of stimulus induced dyskinesia (SID) on the therapeutic outcome of globus pallidus internus (GPi) deep brain stimulation (DBS) for the…PASADENA: A Phase 2 study to evaluate the safety and efficacy of prasinezumab in early Parkinson’s disease; Part 1 Week-52 results
Objective: Evaluate efficacy and safety of prasinezumab following 52 weeks of treatment in participants with early Parkinson’s disease (PD). Background: Prasinezumab is a humanized monoclonal…Phase I Study Design of a Leucine-Rich Repeat Kinase 2 (LRRK2) Antisense Oligonucleotide, for Parkinson’s Disease
Objective: We will present the preclinical efficacy and safety data and the design of the first in human trial of an antisense oligonucleotide (ASO) for…Passive monitored daily motor behavior significantly relates to quality of life in early Parkinson’s disease
Objective: To investigate whether passively acquired measures of gait and hand gestures are associated with health-related quality of life (HrQoL; PDQ-39) and health-state (EQ-5D-5L) in…Spontaneous smoking cessation in a parkinsonian patient treated with apomorphine pump
Objective: To describe the case of a parkinsonian patient treated by apomorphine pump who stopped smoking without difficulty despite being dependent to nicotine. To explore…Efficacy and Safety of Opicapone in Parkinson’s Disease Patients According to Duration of Motor Fluctuations: Post-Hoc Analysis of BIPARK-I and II
Objective: This exploratory post-hoc analysis evaluated the efficacy and safety of opicapone (OPC) in levodopa-treated Parkinson’s disease (PD) patients with duration of motor fluctuations of…Monitoring electrophysiological recordings in patients with LCIJ therapy
Objective: Levodopa carbidopa intestinal jel (LCIJ) treatment for advanced Parkinson’s disease patients is live-saving for the appropriate patients, however follow up of the patients has…Correlation Between Dyskinesia and Quality of Life at Baseline and After 12 months of Treatment with LCIG in Patients with Advanced Parkinson’s Disease
Objective: Evaluate the correlation between dyskinesia and quality of life (QoL) at baseline and after 12 months of treatment with levodopa-carbidopa intestinal gel (LCIG) in…New compound increasing glucocerebrosidase activity on primary cell cultures obtained from patients with GBA-associated Parkinson’s disease
Objective: To determine whether new chemical modifications of the previously described allosteric GCase chaperone N607 (Aflaki E et.al Neurosc. 2016) increase GCase activity in monocyte-derived…
- « Previous Page
- 1
- …
- 8
- 9
- 10
- 11
- 12
- …
- 149
- Next Page »